MEK1 mutations confer resistance to MEK and B-RAF inhibition.
about
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Analysis of the genome to personalize therapy for melanomaMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsThe Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyMelanoma: oncogenic drivers and the immune systemTherapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With ImmunotherapyClinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challengesUniverses collide: combining immunotherapy with targeted therapy for cancerToward a Molecular Classification of Colorectal Cancer: The Role of BRAFEmerging targeted therapies for melanoma treatment (review)The dynamic nature of the kinomePathways and therapeutic targets in melanomaBeyond BRAF: where next for melanoma therapy?Current and future trials of targeted therapies in cutaneous melanomaTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondIn vitro selection of mutant HDM2 resistant to Nutlin inhibitionCIViC databaseMechanisms of drug resistance in kinases.BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAFCabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancerDetailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.Systemic Therapies for Late-stage MelanomaPilocytic astrocytoma: a disease with evolving molecular heterogeneityFunctional profiling of live melanoma samples using a novel automated platformFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentMEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of AutophagyIntra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanomaCOT drives resistance to RAF inhibition through MAP kinase pathway reactivationIdentification of glycogen synthase kinase 3α as a therapeutic target in melanomaReduced NF1 expression confers resistance to EGFR inhibition in lung cancerThe cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance.
P2860
Q24315032-305309A7-2853-4C09-B4BE-F806246808A1Q24601008-8446AA10-AF0B-4982-9E53-EADEAC13571AQ24629474-6B0E5D2A-57B4-4B2D-B5FE-93222D37AF69Q24632064-0B20B07D-50CE-4E1A-9CDF-8812699D26B2Q26747247-29151C05-8FC9-45CA-B8FC-40D5EE4B0D4BQ26771192-C908B417-1D86-41D9-B0BB-6AE0F2166993Q26775598-C819F868-A77A-4298-8776-84B1BDD833FAQ26782222-2B72CECD-0CDD-4E75-8532-B0DF043AF304Q26796309-A28D2DB1-9FD2-476B-9C94-B358B48C7823Q26823978-CAE0F771-E523-484B-9282-0FE5916AF15AQ26825316-D3B53788-7753-4508-96A0-211E3F9A8FA4Q26827212-BF042964-0F9A-4B31-B06B-FE8485D33BA2Q26829997-C316BF22-D7F5-404F-A293-A1069804FE9EQ26852588-2C4DE67C-CA9E-460A-B0EF-9AA2FACB5A72Q26865736-246846C2-EAF2-44FE-96DF-F043708A7A67Q27006853-FF9AF0A6-4F76-423B-A2DD-0886A670CC14Q27022355-B222F769-7B9D-45FC-AD77-E5E2ACF03242Q27026323-C512DA39-F917-4D9E-A08F-16C7AF5DB40DQ27322456-7C8F8142-CBD4-4178-AC76-3CA0B98DBAD1Q27612411-139DB867-1D76-478D-837D-28F75F22FD84Q27692567-7BFB0318-E6E3-4EA2-9A1F-CABDF26573D9Q27851610-D0DCD038-4B90-4090-B17F-86BA0398EDD2Q27851628-C0967143-9EC4-45FA-AC37-170D63AD9C66Q27851672-A9F6D01B-C5E1-44B7-ADC5-63FAE24FB277Q27851856-22D58C9F-6388-4E13-8E21-CD5D99D05AD3Q27852017-436628F0-E336-4ACF-BD80-A15952D81FC7Q27852994-68FD1D89-CF81-4471-A431-AB58A7192CB2Q27853045-60B6D65B-A8BF-4979-BC76-028CC734B08FQ27853086-CABD8BCE-5565-4C23-9968-3EB98BF389D8Q27853105-035A456F-5BEA-44C6-95C8-F936F721F2A2Q28080215-36533646-9403-46C1-9473-DF45921445E0Q28286218-5E2A7EFB-B1F0-48BD-9A7A-820FA45F27A8Q28484649-288D0E47-F5DC-4532-B62D-DA92F491D957Q28533949-E1575545-61FA-4FE5-AF98-382E8B868EA1Q28552218-A5201378-73F4-4711-B13E-C1B88C40030EQ28740547-A33628C3-A2D2-4F80-9FFE-A9E4D4EAC5BFQ29615032-F209BA0D-4891-4A63-BD7D-55C1D05B1C33Q33569998-B615EF6F-69D0-4D01-BBF7-0D8072C99BC7Q33572728-5D8CCBCC-98E7-4339-88B9-37A7051B5C5AQ33618677-E39475C5-9618-4F41-B34C-C75CFD208685
P2860
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
@ast
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
@en
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
@nl
type
label
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
@ast
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
@en
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
@nl
altLabel
MEK1 mutations confer resistance to MEK and B-RAF inhibition
@en
prefLabel
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
@ast
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
@en
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
@nl
P2093
P2860
P3181
P356
P1476
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
@en
P2093
Allison M Sawyer
Caroline M Emery
Charles Hatton
Jessica J Kim
Jianming Zhang
Krishna G Vijayendran
Laura E MacConaill
Maria B Karpova
Marie C Zipser
P2860
P304
P3181
P356
10.1073/PNAS.0905833106
P407
P577
2009-12-01T00:00:00Z